Research News

An international leader in neurofibromatosis research has received a $3.5 million grant to study why people with the same genetic mutation – in this case, a mutation that causes the genetic disorder known as neurofibromatosis…

Removing a brain tumor requires walking a fine line: Remove too little, and the disease remains; remove too much, and sight, speech or movement may be impaired. To help strike that delicate balance, neurosurgeries often…

For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential…

The body of knowledge on cancer genomics is massive and ever-expanding. But this wealth of potentially critical information is far less likely to be of help to patients if it is inaccessible to the doctors…

Conventional wisdom holds that the loss of cells that secrete acid in the stomach leads to a condition that eventually can develop into stomach cancer. But new research at Washington University School of Medicine and…

For decades, scientists have tried to halt cancer by blocking nutrients from reaching tumor cells, in essence starving tumor cells of the fuel needed to grow and proliferate. Such attempts often have disappointed because cancer…

For the first time ever, investigators are studying immunotherapy for patients with newly diagnosed endometrial cancer. The trial uses pembrolizumab, a programmed death receptor-1 (PD-1) inhibitor. The drug is currently approved by the Food and…

Li Ding, PhD, is something of a cryptographer. Or perhaps reverse cryptographer is more accurate. Rather than writing code to conceal meaning, she works to decipher nature’s secret language. Ding and her colleagues design new…

While a particular metabolic pathway shows potential to slow down the aging process, new research indicates a downside: That same pathway may drive brain cancer. The pathway, known as the nicotinamide adenine dinucleotide (NAD+) pathway,…

Patients with the most lethal form of acute myeloid leukemia (AML) – based on genetic profiles of their cancers – typically survive for only four to six months after diagnosis, even with aggressive chemotherapy. But…